On March 19th, the "Shine - Simcere Tumor Summit Forum" hosted by the Chinese Society of Clinical Oncology (CSCO) and co-organized by Simcere Pharmaceuticals was successfully held.
The conference was divided into two venues in Jinan and Guangzhou, and many places participated in online and offline linkage.
Professor Li Baosheng of Shandong Provincial Cancer Hospital, Professor Wang Ping of Cancer Hospital of Tianjin Medical University, Professor Wu Gang of Union Hospital of Huazhong University of Science and Technology served as the chairman of the conference, Professor Zhao Lujun of Cancer Hospital of Tianjin Medical University, Professor Yang Zhe of Shandong Provincial Hospital, Professor Liu Hong of Qilu Hospital of Shandong University, and Professor Yang Jie of the Fourth Hospital of Hebei Medical University served as the moderators of the conference.
Professor Fu Xiaolong of the Chest Hospital Affiliated to Shanghai Jiao Tong University, Professor Wang Lulu of Shenzhen Hospital of Cancer Hospital of Chinese Academy of Medical Sciences served as the chairman of the conference, Professor Lin Qin of the First Affiliated Hospital of Xiamen University, Professor Li Tao of Sichuan Provincial Cancer Hospital, Professor Yang Kunyu of Union Hospital of Huazhong University of Science and Technology, and Professor Bu Junguo of the Second People's Hospital of Guangdong Province served as the moderators of the conference.
A total of 50 well-known clinical oncology experts participated in the conference, with the theme of radiotherapy diagnosis and treatment in the treatment process of non-small cell lung cancer, small cell lung cancer, esophageal cancer, nasopharyngeal carcinoma, etc., a series of in-depth academic discussions were carried out, summarizing the latest progress of radiotherapy combined with chemotherapy, immunotherapy, and anti-vascular therapy, and taking stock of the latest achievements of the Research Project of the Simcere Cancer Research Fund.
Guangzhou venue agenda
Professor Cai Xuwei of Shanghai Chest Hospital shared the "Progress of NSCLC Immunotherapy". Professor Cai introduced the progress of mainstream clinical research at home and abroad on non-small cell lung cancer at different stages in the past two years. The results of the study showed that the combination of Ende and immune checkpoint inhibitors had a synergistic effect, and the combination with a variety of PD-1 monoclonal antibodies had a good tumor suppression rate, which was safe and controllable, and effectively reduced the occurrence of adverse reactions such as RCCEP. The number of people benefiting from immunotherapy continues to expand, and some specific populations excluded from clinical research, such as lung cancer brain metastases, EGFR/ALK resistance, and elderly patients, are constantly being updated and breakthroughs in treatment methods. It is believed that changes in the mode of administration, such as subcutaneous injection, may bring new hope for clinical benefits for a larger patient population.
Professor Wu Jianfeng of Jiangsu Cancer Hospital gave a report entitled "New Progress in NSCLC Anti-Vascular and Targeted Therapy". Professor Wu interpreted the new progress of NSCLC anti-vascular and targeted therapy in 2021 from the perspective of radiotherapy. For locally advanced NSCLCs, Endurance can assist chemoradiotherapy by improving efficacy and reducing the incidence of pneumonia.
Professor Fang Wenfeng of the Affiliated Cancer Hospital of Sun Yat-sen University shared the "Updated Points of the Guidelines for 2021 CSCO Recurrent Metastatic Nasopharyngeal Carcinoma". Professor Fang said: In the CSCO guidelines, for recurrent metastatic nasopharyngeal carcinoma, the first-line treatment plan of "cisplatin + gemcitabine + grace" is recommended. This treatment regimen is effective in shrinking tumors, controlling disease progression, and improving prognosis, on par with current protocols using PD-1.
Professor Li Jiancheng of Fujian Provincial Cancer Hospital gave a report entitled "Mechanism of Action of Recombinant Human Vascular Endostatin combined with Chemoradiotherapy and Interpretation of Research Progress in Late NSCLC". Professor Li shared the progress of the study on the mechanism of action of Endu combined chemoradiotherapy and the research in late NSCLC: Compared with bevacizumab, Endu effectively reduced the incidence of pneumonia above grade 2 in patients with locally advanced NSCLC with simultaneous chemoradiotherapy, and it was also suitable for patients with poor cardiopulmonary function.
Professor Li Zihuang of Shenzhen People's Hospital reported that the topic was "Progress and Reflections on the Treatment of Small Cell Lung Cancer". Professor Li introduced the clinical application of PD-L1 in common thoracic tumors and the first phase I/II clinical study of emvoliumab, a domestic subcutaneous injection of PD-L1 inhibitor. PD-L1 inhibitor combined with chemotherapy first-line treatment of ES-SCLC mOS for more than 1 year, immunotherapy for the first time to get clinical guidelines recommended; envolizumab is a new generation of subcutaneous PD-L1 inhibitors, which are characterized by small molecular weight, high affinity, stable structure, and subcutaneous injection of the use of the route, have ensured its excellent short-term efficacy, significantly improve patient compliance and quality of life, the current Enveda in small cell lung cancer exploration research is underway, worth looking forward to!
Jinan venue agenda
Professor Liu Ningbo of Tianjin Medical University Cancer Hospital shared the "Progress of NSCLC Immunotherapy". Professor Liu shared the new progress of immunotherapy for non-small cell lung cancer, and introduced the clinical studies of immunotherapy for non-small cell lung cancer in early, late and advanced stages and some special populations according to the literature released by WCLC, ESMO and CSCO in 2021. A number of clinical studies have proved the effectiveness and safety of Endo combined immunotherapy, and there is still unlimited room for exploration of the treatment methods combined with anti-angiogenesis drugs and immunotherapy.
Professor Liu Xijun of Shandong Provincial Cancer Hospital reported that the topic was "New Progress in NSCLC Anti-Vascular and Targeted Therapy". Professor Liu said that the latest research on anti-vascular drugs proves that there is no significant difference between the continuous pumping of recombinant human vascular endostatin and intravenous infusion on the treatment effect of NSCLC, and it is an optional route of medication. And Endu in combination with simultaneous radiotherapy and chemotherapy can reduce the incidence of radiation pneumonia and improve safety.
Professor Wu Hui of Henan Provincial Cancer Hospital shared the "Key Points of The Update of the Guidelines for CSCO Nasopharyngeal Cancer - Comprehensive Treatment of Advanced Nasopharyngeal Cancer". Professor Wu reviewed the key points of the guidelines for the comprehensive treatment of advanced nasopharyngeal carcinoma in 2020, interpreted the guideline update for the comprehensive treatment of advanced nasopharyngeal carcinoma in 2021, and looked forward to the future development trend of advanced nasopharyngeal cancer treatment options. Professor Wu said that the endurance and GP protocols have joined the first-line treatment plan of the 2021 CSCO Nasopharyngeal Cancer Diagnosis and Treatment Guidelines, proving that its effectiveness has been recognized.
The topic of the report by Lu Haijun Professor of the Affiliated Hospital of Qingdao University is "Recombinant Human Vascular Endothelial Suppressin combined with Radiotherapy and Chemotherapy Mechanism and Interpretation of the Research Progress of Late NSCLC". In addition to the research progress, Professor Lu also reviewed Endu's HELPER research. He has reviewed clinical trials in the treatment of advanced stages of non-small lung cancer, demonstrating that Ende has a sensitizing effect on chemoradiotherapy and can produce a "1+1>2" effect.
Professor Wang Tiejun of the Second Hospital of Jilin University shared the "Interpretation of research progress of recombinant human vascular endothelial inhibin combined with radiotherapy and chemotherapy- extrapulmonary field". Professor Wang made research progress on the three diseases of Endu combined chemoradiotherapy in the field of extrapulmonary areas, mainly nasopharyngeal carcinoma, esophageal cancer and cervical cancer. Professor Wang said that multiple studies have verified the sensitizing effect and excellent safety of Endu on chemoradiotherapy and chemotherapy, as well as its effectiveness in the treatment of nasopharyngeal cancer, esophageal cancer and cervical cancer, and has been recommended by the 2020 China Guidelines for Radiation Therapy for Esophageal Cancer.
Professor Zhu Hui of Shandong Provincial Cancer Hospital reported that the topic was "Application of PD-L1 Inhibitor Combined Radiotherapy in Tumor Treatment". Professor Zhu introduced the clinical application of PD-L1 in common thoracic tumors and the first phase I/II clinical study of emvoliumab, a domestic subcutaneous injection of PD-L1 inhibitor. Envolizumab is characterized by its small molecular weight, high affinity, stable structure, and subcutaneous injection route, which ensures excellent short-term efficacy and significantly improves patient compliance and quality of life.
Finally, the President of the Conference summarized today's meeting and expressed his expectations for the exploration of future anti-angiogenesis drugs and the combination of immunotherapy and radiotherapy.
Academic Conference Preview
The conference ended successfully, but the pace of academic progress did not stop. On May 19, the second national finals of the Target Area Sketching Competition will be held on May 19, and the review meeting of the Second Phase of radiotherapy field Simcere Oncology Research Fund will be held on June 10.
Simcere Pharmaceutical has always been adhering to the mission of "allowing patients to use more effective drugs as soon as possible" and constantly moving forward.